Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of <scp>PCSK9</scp> Inhibitor Treatment Initiation Post Myocardial Infarction
The clone-censor-weight method is a promising approach that allows researchers to answer questions about the effect of treatment policies. But practical guidance is needed to address problems that arise from small, highly imbalanced groups, which is common with most newly introduced treatments.
Authors
- Shia T. Kent (ORCID: https://orcid.org/0000-0002-2891-4520)
- Stefan Gustafsson (ORCID: https://orcid.org/0000-0001-5894-0351)
- A. K. Gitt
- S. James
- Thomas Cars (ORCID: https://orcid.org/0009-0008-0912-8226)
- Johan Sundström (ORCID: https://orcid.org/0000-0003-2247-8454)
- Queenie Chan (ORCID: https://orcid.org/0000-0001-9278-230X)
- Andrew Briggs
- Emil Hagström
- Nafeesa Dhalwani
- Philippe Gabriel Steg
- J. Wouter Jukema
- M. Alan Brookhart
- Chris P. Gale
Institutions
- Uppsala University (SE)
- University of Leeds (GB)
- Amgen (United States) (US)
- Inserm (FR)
- Duke University (US)
- Ludwigshafen University of Business and Society (DE)
- Leiden University Medical Center (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Sorbonne Paris Cité (FR)
- Olink Bioscience (Sweden) (SE)
- Amgen (United Kingdom) (GB)
- Klinikum Ludwigshafen (DE)
- Duke University Health System (US)
- Hôpital Bichat-Claude-Bernard (FR)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1002/pds.70354
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00